Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?

被引:2
作者
Yamada, Ruriko [1 ]
Maeda, Nagamasa [1 ]
Oguri, Hiroyoshi [1 ]
Adachi, Yoshihiro [2 ]
Takeuchi, Tamotsu [2 ]
Furihata, Mutsuo [2 ]
Fukaya, Takao [1 ]
机构
[1] Kochi Med Sch, Dept Obstet & Gynecol, Kochi 7838505, Japan
[2] Kochi Med Sch, Dept Pathol, Kochi 7838505, Japan
关键词
Cystic ovarian tumor; Cystic fluid; p53; Gene mutation; P53; MUTATION; ALLELIC DELETION; GENE-MUTATIONS; ENDOMETRIOSIS; CANCER; ACCUMULATION; EXPRESSION; PROTEIN; BENIGN; WOMEN;
D O I
10.1016/j.ejogrb.2013.08.003
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: p53 gene mutations are frequently identified in ovarian cancer tissue. The aim of this study was to investigate whether wild type or mutated genomic DNA can be identified in ovarian cystic fluid specimens. Study design: Forty-eight Japanese patients with cystic ovarian tumors (30 benign cysts, 8 borderline malignant tumors, and 10 cancers) were investigated. Cystic fluid and tumor tissue were obtained during surgery. After DNA extraction from the cystic fluid, polymerase chain reaction (PCR) and sequence analysis for exons 4-9 of the p53 gene was performed. In two cases of mucinous cystic tumor of borderline malignancy and endometrioid adenocarcinoma, the p53 gene sequences were determined. Immunohistochemical staining for abnormal p53 gene product was also performed. Results: DNA was successfully extracted from all cystic fluid specimens. Furthermore, exons 4-9 of the p53 gene could be identified by electrophoresis from all samples. In a mucinous cystic tumor of borderline malignancy, one point mutation was identified at codon 223 in exon 6 (CCT -> CTT) of the p53 gene. Aberrant p53 gene product was also observed in the tumor cells by immunohistochemical staining. Moreover, in another case of endometrial adenocarcinoma, a point mutation at codon 245 in exon 7 (GGC -> AGC) was detected by the direct sequencing of the amplified Exon. Notably, the mutation was not present in the peripheral blood (PB) sample and tissue specimens from the patient. Conclusion: In cystic ovarian tumors, cystic fluid may provide informative material for molecular studies since it reflects the p53 status of tumor tissue in the cyst wall. This system might help to identify ovarian malignancy without resection of the tumor tissues. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:96 / 100
页数:5
相关论文
共 25 条
[1]   The role of p53 mutation in the carcinomas arising from endometriosis [J].
Akahane, Tomoko ;
Sekizawa, Akihiko ;
Purwosunu, Yuditiya ;
Nagatsuka, Masaaki ;
Okai, Takashi .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2007, 26 (03) :345-351
[2]   Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: Response to cisplatin-based chemotherapy [J].
Bar, JK ;
Harlozinska, A ;
Popiela, A ;
Noga, L .
TUMOR BIOLOGY, 2001, 22 (02) :83-91
[3]   Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors [J].
Brinton, LA ;
Sakoda, LC ;
Sherman, ME ;
Frederiksen, K ;
Kjaer, SK ;
Graubard, BI ;
Olsen, JH ;
Mellemkjaer, L .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (12) :2929-2935
[4]  
Christie Michael, 2006, J Br Menopause Soc, V12, P57, DOI 10.1258/136218006777525794
[5]   Aspiration cytology of neoplastic and non-neoplastic ovarian cysts: Is it accurate? [J].
Ganjei, P ;
Dickinson, B ;
Harrison, TA ;
Nassiri, M ;
Lu, Y .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (02) :94-101
[6]  
Gojnic M, 2006, EUR J GYNAECOL ONCOL, V27, P271
[7]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[8]  
Jiang XX, 1996, CANCER RES, V56, P3534
[9]   HIGH-INCIDENCE OF P53 GENE MUTATION IN HUMAN OVARIAN-CANCER AND ITS ASSOCIATION WITH NUCLEAR ACCUMULATION OF P53 PROTEIN AND TUMOR DNA ANEUPLOIDY [J].
KIHANA, T ;
TSUDA, H ;
TESHIMA, S ;
OKADA, S ;
MATSUURA, S ;
HIROHASHI, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (09) :978-984
[10]   A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors [J].
Kmet, LM ;
Cook, LS ;
Magliocco, AM .
CANCER, 2003, 97 (02) :389-404